Skin and skin structure infections: treatment with newer generation fluoroquinolones. - Wikidata - wikimedia - TriplyDB

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

http://www.wikidata.org/entity/Q37116838

about

Antibacterial Evaluation of Synthetic Thiazole Compounds In Vitro and In Vivo in a Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infection Mouse Model Hyaluronan breakdown contributes to immune defense against group A Streptococcus Global fluoroquinolone resistance epidemiology and implictions for clinical use.Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus Anti-infectious and anti-inflammatory effects of peptide fragments sequentially derived from the antimicrobial peptide centrocin 1 isolated from the green sea urchin, Strongylocentrotus droebachiensis.Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns.A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent Clostridium difficile infection.Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.Preparation oral levofloxacin colon-specific microspheres delivery: in vitro and in vivo studies.Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens.

P2860

Q28550691-9186F5B9-F2C2-4E66-864B-BB1C01A6BB02 Q34245010-97A6CE5F-B7E5-4BFF-9F40-59533F321B49 Q36337074-4AA37425-C637-49DA-8185-942BD4F87607 Q36392641-0A450F08-6C0B-4354-9844-705BF3F1AD90 Q36578817-10EB5911-8A6F-4C3E-8CFF-95AF39CAA37A Q36997690-2349CFC8-5963-436B-B1E6-09490BC3FB6B Q37678156-162B46C0-F139-4FA4-B230-5EBE98FE03A0 Q37688458-7E448B70-1E61-48AD-A989-81D157F9763E Q40313144-FEE8B8C6-45DA-4A55-8140-539FAA98EF3A Q53523560-13CA70D7-4088-4A15-BE85-471DA679F6E0 Q55432018-1EAD7B3D-728B-4B60-BFF6-EC830A38ADF5

P2860

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

http://www.wikidata.org/entity/Q37116838

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

@en

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

@nl

type

label

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

@en

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

@nl

prefLabel

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

@en

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

@nl

P1433

Q37116838-30AED3CF-7E2D-40BC-8E95-640FF63B4629

P1476

Q37116838-3B3C6A95-8C43-4E76-BE32-DEBB05299F1D

P2093

Q37116838-329439B7-B125-404C-9D3B-CE372F8C14C1

Q37116838-5562D906-E2FE-4C5D-8184-A30D44F058A8

Q37116838-72B9D68C-12BC-42EC-9ADF-05058CEF4346

Q37116838-FCF9193A-FAA7-45E0-83A5-6137ECBC5D5F

P2860

Q37116838-02DDEB18-6F6E-43ED-9C4E-0080244B370B

Q37116838-042F8A96-31F6-4D16-87A0-7D5439818B72

Q37116838-089E36BE-703C-4A1B-9881-95B062A925B0

Q37116838-0A6E70EF-C68C-4170-A74C-7C55838BE1A7

Q37116838-107AD37A-B0C7-45EF-85A9-A0001B180E01

Q37116838-156621D6-DA69-4E96-8C17-00A47C8EBF48

Q37116838-16EDC841-F0B1-48EB-A011-077159291F0F

Q37116838-19FBC252-38F5-4B76-BA46-472B0EA9F027

Q37116838-1BAE13DF-C570-4936-9049-3825C53D9DC1

Q37116838-1C7F5BFC-DE08-4D4B-807A-DFFED4BB0627

P304

Q37116838-0E60BE32-EF23-4032-92BF-2A47FD115349

P31

Q37116838-37D713DF-A3AE-42D6-A630-D05566294B59

P356

Q37116838-A82A89C5-84BC-4EBF-9058-551FC1A28246

P433

Q37116838-EF2A3D64-29BC-4FBE-BBF2-5E9405DD9855

P478

Q37116838-33EC9FA2-7F4F-4904-B1C7-1BBA304583B4

P577

Q37116838-C4FA319B-BAE8-4E00-89FE-566441FB3E52

P5875

Q37116838-FA20FCCA-1D91-45FC-8D94-D441AA15F5F5

P698

Q37116838-BF4F805D-1A79-456F-A41F-BB234E62A255

P932

Q37116838-CEC70C68-C845-4BA1-8119-CBA8F7CDF765

P356

TCRM.2007.3.2.309

P1433

Therapeutics and Clinical Risk Management

P1476

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

@en

P2093

Gail Gesin

http://www.w3.org/2001/XMLSchema#string

Jason Kubert

http://www.w3.org/2001/XMLSchema#string

Kurt Weber

http://www.w3.org/2001/XMLSchema#string

Philip Giordano

http://www.w3.org/2001/XMLSchema#string

P2860

Drug induced QT prolongation and torsades de pointes

Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

Gatifloxacin-induced QTc prolongation and ventricular tachycardia.

Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.

Optimal treatment of complicated skin and skin structure infections.

In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.

Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.

P304

309-317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.2007.3.2.309

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5491036

http://www.w3.org/2001/XMLSchema#string

P698

18360639

http://www.w3.org/2001/XMLSchema#string

P932

1936312

http://www.w3.org/2001/XMLSchema#string